



## Retrophin to Report Fourth Quarter and Full Year 2015 Financial Results

February 11, 2016

SAN DIEGO, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2015 financial results on Thursday, February 25, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

### Conference Call Information

Date: Thursday, February 25, 2016

Time: 4:30 p.m. ET

Dial-in numbers: +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)

Confirmation code: 49757304

Live webcast: [www.retrophin.com](http://www.retrophin.com) in the "Events & Presentations" section of the "Investors" page

A replay of the call will be available 7:30 p.m. ET, February 25, 2016 to 11:59 p.m. ET, March 3, 2016. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 49757304.

### About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with no approved treatment options, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the company's marketed products, Chenodal<sup>®</sup>, Cholbam<sup>®</sup> and Thiola<sup>®</sup>.

[Retrophin.com](http://Retrophin.com)

Contact:

Chris Cline, CFA

Director, Investor Relations

646-564-3680

[IR@retrophin.com](mailto:IR@retrophin.com)

The logo for Retrophin, featuring the word "Retrophin" in a bold, sans-serif font. The letter "R" is significantly larger and more prominent than the other letters, and the entire word is enclosed in a thin rectangular border.

Source: Retrophin, Inc.

News Provided by Acquire Media